Summit Global Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Summit Global Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-67,883	Closed	-$12.1M	–	518
2021 Q2	$12.1M	Buy	+67,883	New	+$11.8M	0.72%	25
2020 Q1	–	Sell	-10,515	Closed	-$1.57M	–	256
2019 Q4	$1.57M	Buy	10,515 +202	+2%	+$27.5K	0.17%	95
2019 Q3	$1.32M	Buy	10,313 +1,400	+16%	+$188K	0.15%	107
2019 Q2	$1.27M	Sell	8,913 -2	-0%	-$269	0.16%	110
2019 Q1	$1.27M	Buy	8,915 +915	+11%	+$119K	0.16%	106
2018 Q4	$992K	Buy	+8,000	New	+$1.19M	0.15%	101

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Summit Global Investments's JAZZ Position: Q3 2021 in Review

Summit Global Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 67,883 shares — an estimated $12.1M sold.

Summit Global Investments first reported a position in JAZZ in Q4 2018 and held it in 6 quarters. The position peaked at $12.1M in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Summit Global Investments reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Summit Global Investments sold 67,883 Jazz Pharmaceuticals shares in Q3 2021, an estimated $12.1M.
Summit Global Investments first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Summit Global Investments's Jazz Pharmaceuticals position peaked at $12.1M in Q2 2021.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Summit Global Investments's 13F filing for Q3 2021, filed 8 Nov 2021.